<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00486226</url>
  </required_header>
  <id_info>
    <org_study_id>EN07-01</org_study_id>
    <nct_id>NCT00486226</nct_id>
  </id_info>
  <brief_title>The Registry to Study Safety and Performance of the CORDIS Vascular Reconstruction Device and Delivery System</brief_title>
  <acronym>SUNRISE</acronym>
  <official_title>The SUNRISE Registry - A Multicenter Post-Market Surveillance With the CORDIS ENTERPRISE™ Vascular Reconstruction Device and Delivery System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Codman &amp; Shurtleff</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Codman &amp; Shurtleff</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the registry is to evaluate the real world safety and performance of the
      CORDIS ENTERPRISE™ Vascular Reconstruction Device and Delivery System (VRD) to facilitate
      endovascular coil embolization of intracranial aneurysms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The data will be collected in consecutive subjects treated with the commercially available
      product and following standard clinical practice. This registry will be limited to subjects
      who have received only the CORDIS ENTERPRISE™ VRD during the index procedure. While only
      limited inclusion or exclusion criteria are specified, uniform, complete and accurate data
      will be collected peri-procedurally, during the index hospitalization, and during follow-up
      up to 6 months. All subjects should be treated according to the Instruction For Use (IFU)
      including conduct of the VRD placement, coiling procedure, application of antiplatelet
      medication and any other medical therapy to be provided according to local usual practice.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Successful Intracranial VRD Placement With Satisfactory Coil Mass Position Without the Occurrence of Any Device and/or Procedure Related Serious Adverse Event (SAE)</measure>
    <time_frame>Start of the procedure to end of the procedure (defined as removal of catheter sheath introducer after the coiling procedure)</time_frame>
    <description>Successful intracranial VRD placement is defined as stable VRD placement with complete coverage of the aneurysm neck and parent artery patency.
Satisfactory coil mass position is defined as VRD maintains coil position within the sac with parent artery patency as defined angiographically</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device or Procedure Related Adverse Events (AEs)</measure>
    <time_frame>index procedure to discharge; an average of 3.8 days</time_frame>
    <description>Incidence of device or procedure related adverse events during the index procedure and till discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfactory Coil Mass Position</measure>
    <time_frame>6 months</time_frame>
    <description>Satisfactory coil mass position is defined as VRD maintains coil position within the sac with parent artery patency as defined angiographically</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aneurysm Occlusion</measure>
    <time_frame>post procedure to 6 months</time_frame>
    <description>Aneurysm occlusion was assessed using the Raymond Scale (Class 1 - Complete Obliteration / Class 2 - Residual Neck / Class 3 - Residual Aneurysm)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Intracranial Aneurysm</condition>
  <arm_group>
    <arm_group_label>1 Endovascular</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients implanted with an CORDIS ENTERPRISE Vascular Reconstruction Device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vascular Reconstruction Device</intervention_name>
    <description>CORDIS ENTERPRISE™ VRD</description>
    <arm_group_label>1 Endovascular</arm_group_label>
    <other_name>ENTERPRISE</other_name>
    <other_name>Codman ENTERPRISE</other_name>
    <other_name>Codman VRD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject must be &gt;= 18 years of age and less than 80 years.

          -  Diagnosis of a ruptured (Hunt and Hess Grade I - III) or unruptured intracranial
             aneurysm at the time of the treatment

          -  Subject (or his/her legal representative) provides written informed consent for the
             use of his/her peri-procedural and follow-up data

        Exclusion Criteria:

          -  Diagnosis of Hunt and Hess Grade IV or V subarachnoid hemorrhage at the time of the
             treatment

          -  Severe co-morbidity associated with a life-expectancy of less than six months

          -  Poor neurological status at baseline

          -  Known allergies to Nitinol metal

          -  Known allergies to aspirin, heparin, ticlopidine, or clopidogrel or unable or
             unwilling to tolerate therapy

          -  Participation in an investigational drug or another device study is only allowed after
             written approval of the coordinating investigator or Cordis Medical Monitor.

          -  Implantation of an intracranial stent associated with the symptomatic distribution
             within 12 weeks prior to the index procedure

          -  Implantation of carotid stent associated with the symptomatic distribution within 12
             weeks prior to the index procedure

          -  Atrial fibrillation or known cardiac disorders likely to be associated with
             cardioembolic symptoms.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bendszus Martin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wuerzburg University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Boris Lubicz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université Libre de Bruxelles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Université Libre de Bruxelles</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2007</study_first_submitted>
  <study_first_submitted_qc>June 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2007</study_first_posted>
  <results_first_submitted>January 8, 2014</results_first_submitted>
  <results_first_submitted_qc>March 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 21, 2014</results_first_posted>
  <last_update_submitted>March 19, 2014</last_update_submitted>
  <last_update_submitted_qc>March 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Intracranial Aneurysm</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1 Endovascular</title>
          <description>All patients implanted with an CORDIS ENTERPRISE Vascular Reconstruction Device (VRD).
Vascular Reconstruction Device: CORDIS ENTERPRISE™ VRD</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 Endovascular</title>
          <description>All patients implanted with an CORDIS ENTERPRISE Vascular Reconstruction Device and were consented before the procedure.
Vascular Reconstruction Device: CORDIS ENTERPRISE™ VRD</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="105"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.3" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medical History</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic Pulmonary Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immunologic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endocrice/Metabolic Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyslipidemia/Hypercolesterolemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasculitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obesity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Neurological History</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>TIA/CVA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recurrent Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epilepsy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cranial Nerve Palsy/ Paresis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Neurological Surgical Procedures</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Successful Intracranial VRD Placement With Satisfactory Coil Mass Position Without the Occurrence of Any Device and/or Procedure Related Serious Adverse Event (SAE)</title>
        <description>Successful intracranial VRD placement is defined as stable VRD placement with complete coverage of the aneurysm neck and parent artery patency.
Satisfactory coil mass position is defined as VRD maintains coil position within the sac with parent artery patency as defined angiographically</description>
        <time_frame>Start of the procedure to end of the procedure (defined as removal of catheter sheath introducer after the coiling procedure)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Endovascular</title>
            <description>All patients implanted with an CORDIS ENTERPRISE Vascular Reconstruction Device who signed consent before the procedure.
Vascular Reconstruction Device: CORDIS ENTERPRISE™ VRD</description>
          </group>
        </group_list>
        <measure>
          <title>The Successful Intracranial VRD Placement With Satisfactory Coil Mass Position Without the Occurrence of Any Device and/or Procedure Related Serious Adverse Event (SAE)</title>
          <description>Successful intracranial VRD placement is defined as stable VRD placement with complete coverage of the aneurysm neck and parent artery patency.
Satisfactory coil mass position is defined as VRD maintains coil position within the sac with parent artery patency as defined angiographically</description>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="51.6" upper_limit="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device or Procedure Related Adverse Events (AEs)</title>
        <description>Incidence of device or procedure related adverse events during the index procedure and till discharge</description>
        <time_frame>index procedure to discharge; an average of 3.8 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Endovascular</title>
            <description>All patients implanted with an CORDIS ENTERPRISE Vascular Reconstruction Device.
Vascular Reconstruction Device: CORDIS ENTERPRISE™ VRD</description>
          </group>
        </group_list>
        <measure>
          <title>Device or Procedure Related Adverse Events (AEs)</title>
          <description>Incidence of device or procedure related adverse events during the index procedure and till discharge</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Satisfactory Coil Mass Position</title>
        <description>Satisfactory coil mass position is defined as VRD maintains coil position within the sac with parent artery patency as defined angiographically</description>
        <time_frame>6 months</time_frame>
        <population>no data was available for 33 subjects; either because the investigator didn't submit the images or due to poor quality of the submitted images</population>
        <group_list>
          <group group_id="O1">
            <title>1 Endovascular</title>
            <description>All patients implanted with an CORDIS ENTERPRISE Vascular Reconstruction Device who signed consent before the procedure.
Vascular Reconstruction Device: CORDIS ENTERPRISE™ VRD</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfactory Coil Mass Position</title>
          <description>Satisfactory coil mass position is defined as VRD maintains coil position within the sac with parent artery patency as defined angiographically</description>
          <population>no data was available for 33 subjects; either because the investigator didn't submit the images or due to poor quality of the submitted images</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aneurysm Occlusion</title>
        <description>Aneurysm occlusion was assessed using the Raymond Scale (Class 1 - Complete Obliteration / Class 2 - Residual Neck / Class 3 - Residual Aneurysm)</description>
        <time_frame>post procedure to 6 months</time_frame>
        <population>no data was available for 21 subjects post-procedure and 26 subjects at 6 months follow-up; either because the investigator didn't submit the images or due to poor quality of the submitted images</population>
        <group_list>
          <group group_id="O1">
            <title>Endovascular - Occlusion Results Immediately Post-procedure</title>
            <description>Aneurysm occlusion was assessed immediately post procedure using the Raymond Scale.</description>
          </group>
          <group group_id="O2">
            <title>Endovascular - Occlusion Results at 6 Months Follow-up</title>
            <description>Aneurysm occlusion assessed at 6 months follow-up using the Raymond Scale.</description>
          </group>
        </group_list>
        <measure>
          <title>Aneurysm Occlusion</title>
          <description>Aneurysm occlusion was assessed using the Raymond Scale (Class 1 - Complete Obliteration / Class 2 - Residual Neck / Class 3 - Residual Aneurysm)</description>
          <population>no data was available for 21 subjects post-procedure and 26 subjects at 6 months follow-up; either because the investigator didn't submit the images or due to poor quality of the submitted images</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Occlusion (Raymond 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neck Remnant (Raymond 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Residual Aneurysm (Raymond 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>procedure until 6 months follow-up</time_frame>
      <desc>At each evaluation of a subject enrolled in the registry (procedure, discharge, 6 months follow-up) the investigator determined whether any adverse events had occurred.</desc>
      <group_list>
        <group group_id="E1">
          <title>1 Endovascular</title>
          <description>All patients implanted with an CORDIS ENTERPRISE Vascular Reconstruction Device who signed consent before the procedure.
Vascular Reconstruction Device: CORDIS ENTERPRISE™ VRD</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>retroperitoneal hematoma</sub_title>
                <description>retroperitoneal hematoma requiring additional hospitalization</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>stent thrombosis</sub_title>
                <description>Incomplete stent thrombosis started after stent and first coil placement.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischemic Stroke</sub_title>
                <description>Ischemic Stroke in a different territory than the stented one</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <description>Lung metastasis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <description>Left superior limb thrombophlebitis and atrial fibrillation Headache and right hemiparesis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>cholangitis with septicemia</sub_title>
                <description>moderate sclerosing cholangitis post cholecystectomy and septicemia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>stent thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>coil protrusion</sub_title>
                <description>In four subjects coil protrusion occurred before placement of the Enterprise stent and was hence not related to the device. In the remaining subject the timing of coil protrusion (before/after stent placement) was not specified by the investigator.</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>stent migration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>stretched/unravelled coil</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Phasic Disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>embolization/ re-embolization of non-study aneurysm</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>perforator infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>subdural hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>visual disturbances with cintilating scotoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>temporo-spatial disorientation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was powered to have a total of 250 subjects, but was stopped early due to slow enrollment. Hence, this study ended up having only 105 total subjects, making it underpowered.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Arnaud Nicolas</name_or_title>
      <organization>Codman&amp;Shurtleff</organization>
      <phone>+33 0 155 004 543</phone>
      <email>anicolas@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

